Speaker :

Dr. Suman Karanth, Medical Oncologist, Delhi

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Author: Javier Cortes 

Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1000-1000

Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Author: Hope S. Rugo 

Citation: SABCS 2020 GS3-01